Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in moderate to severe atopic dermatitis
NCT03422822Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Mar 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03422822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422822.